- Investor's Business Daily•3 hours ago
Kite Pharma showed better-than-expected results for a Phase II trial for its treatment for Non-Hodgkin lymphoma.
- Benzinga•9 hours ago
Kite Pharma Inc (NASDAQ: KITE ) saw its shares rally sharply in the after hours Tuesday. The reason: Interim results from the Phase II clinical trial of its lead cancer drug candidate, named KTE-C19, meant ...
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||80.08 x 300|
|Ask||80.87 x 100|
|Day's Range||79.71 - 80.90|
|52wk Range||69.90 - 95.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.88|
|Avg Vol (3m)||1,329,954|
|Dividend & Yield||2.72 (3.34%)|